We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Dalteparin for Unstable Angina and Non–Q-Wave Myocardial Infarction

Javier Borja, MD
Arch Intern Med. 2000;160(20):3169-3170. doi:.
Text Size: A A A
Published online


I read with interest the review article by Weitz and Bates1 concerning new treatments for unstable angina and non–Q-wave myocardial infarction, which appeared in the March 27, 2000, issue of the ARCHIVES. I would like to comment about some aspects of the article.

With respect to low-molecular-weight heparins, only the Fragmin During Instability in Coronary Artery Disease (FRISC),2 Fragmin in Unstable Coronary Artery Disease (FRIC),3 Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events (ESSENCE),4 and Thrombolysis in Myocardial Infarction (TIMI) 11B5 studies were considered in this review, and the authors conclude in the "Comment" section that 1 low-molecular-weight heparin (enoxaparin) has shown benefit in patients with unstable angina or non–Q-wave myocardial infarction. Results of the TIMI 11B5 trial were published in October 1999, but, previously, in August 1999, the results of the FRISC II study6 were published, and, surprisingly, they were not analyzed by Weitz and Bates. Moreover, Weitz and Bates' manuscript was accepted for publication June 29, 1999. The omission of analysis of the FRISC II study6 could result in incomplete information about the role of low-molecular-weight heparins in the treatment of the acute coronary syndromes.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles